Dr Ekaphop Sirachainan, president of the Thai Society of Clinical Oncology, explains the need to increase patient access to oncology treatment in…

Janssen's EMEA market access head Martin Price outlines the regulatory changes that need to be made for patients across Europe to better access…

From her vantage point as associate vice president for MSD's Central & Eastern Europe (CEE) cluster, Gabriele Grom outlines the disparity that…

Ines Perea, general manager for Spain and Portugal at Jazz Pharmaceuticals, a global biopharmaceutical company dedicated to developing life-changing…

Dr Jin Hyoung Kang, president of the Cancer Study Group comments on the scope for oncology drug development in Korea, and the issues resulting from…

Yacine Sellam, president of the Algerian Society for Regulatory Affairs & Pharmacoeconomics, outlines the progress made under Algeria's National…

Professor Dae Ho Lee has been researching and treating Korean cancer patients for more than 20 years and advises the current government on healthcare…

Our contributor at large, David Crean, Managing Director for Objective Capital Partners, attended J.P. Morgan's 2019 Health Care Investor…

Frédéric Collet, president Novartis France and general manager oncology explains the rationale behind Novartis’s consistent investment in…

Maria Begona Barragan Garcia, president of GEPAC – the Spanish Group of Patients with Cancer – discusses the necessity of the group and its role…

Last week, Bristol-Myers Squibb (BMS) announced that they have entered into a definitive merger agreement under which Bristol-Myers Squibb will…

National OncoVenture (NOV) is Korea’s Ministry of Health and Welfare funded oncology drug development program to nurture oncology innovation in the…